



DETECTION OF NID FACTOR IN LACTOBIONIC ACID WITH LIMULUS AMOEOCYTE LYSATE

*RAMESH PENNAMAREDDY AND DR. K.PRABAKAR

P.G. Department of Zoology, Jamal Mohamed College(Autonomous), Tiruchirappalli, Tamil Nadu, Pin:620020

E mail: bacterialendotoxin@gmail.com

Received: 17 Jan 2010, Revised and Accepted: 29 Jan 2010

ABSTRACT

Lactobionic acid is used in organ preservative during organ transplant. The effect of varying the pH and ionic strength in Lactobionic acid was investigated. The interfering factors inhibiting the endotoxins in Lactobionic acid while quantifying with Limulus Amoebocyte Lysate was sorted out by neutralizing the ionic concentration in sample using alkali and validated the test sample. Lactobionic acid is weak acid and having pH in the range 1 to 2. Since it is a weak acid its ionic dissociation is very less. As we add strong alkali like NaOH in to it, the pH rises immediately and after some time it comes down to acidic range. After adjusting the pH the sample to be analyzed within an hour to avoid interference.

Keywords: Interference, Limulus Amoebocyte Lysate (LAL), Control Standard Endotoxin (CSE), Non-Inhibitory dilution (NID).

INTRODUCTION

Bacterial Endotoxin is one of the most potent activator of mammalian immune system. In general, as per the United State Pharmacopeias (USP) the threshold pyrogenic dose is 5 EU/kg/hr for parenteral drugs and 0.2 EU/kg/hr for intrathecal drugs⁵. When endotoxin enters into human blood these toxins induces white blood cells (WBC) to release cytokines, such as tissue necrosis factor (TNF), interleukin-1 and interleukin-8, which mediate a complex biological response including pyrogenicity, shock, coagulation and inflammation^{1, 2&3}. Gram negative bacterial outer membrane Lipopolysacchride (LPS) induces a cascade of defense mechanism that is known as fever and inflammation⁴. So it is mandatory to check the presence of Endotoxin level in Organ preservative before using it for preservation of organs during transplant.

The LAL reaction with endotoxin requires pH neutrality and optimum levels of Na⁺ and divalent cations. A uniform temperature of 37°C optimizes the rate of reaction. Most therapeutic drug products requires dilution with LAL reagent water (LRW) before testing to avoid interference, where inhibition is failure to recover the positive control, and enhancement is excess recovery. There are 3 principle causes of invalid or inhibitory results in gel clot testing are 1. Loss of purified Endotoxin used for product positive controls (PPC). 2. Adverse chemical conditions such as non-neutral pH or sub optimal levels of sodium ions and divalent cations (Mg⁺⁺ and Ca⁺⁺). 3. Inadequate controlled test parameters including testing accessories, reagents and analyst proficiency.

The aim of the study is to sort out the interfering factors which lead to the diverse results in Lactobionic acid. The false positive results may cause severe complication in the patients as discussed in literature.

MATERIALS AND METHODS

Lyophilized Limulus Amoebocyte Lysate of 0.0312 sensitivity (LAL), control standard endotoxin 5 Eu/ng (CSE), LAL reagent water (LRW) of Endosafe US, Depyrogenated (250°C for 30 min) 10 X 75 mm assay tubes, 16 X 100 mm dilution tubes, pyrogen free Micropipette tips, vortex mixture, 1N NaoH and Lactobionic acid were used for determination of Endotoxin content by the gel clot technique.

The sensitivity of the Lysate (labeled 0.0312 Eu/mL) was determined by using known amount of E.coli control standard Endotoxin.

In the gel-clot techniques, the reaction end point is determined from dilutions of the material under test in direct comparison with parallel dilutions or a reference Endotoxin, and quantities of endotoxins are expressed in Endotoxin units.

1. Preparation of Standard stock solution and standard solutions: The CSE having a defined potency of 50 EU/Vial was reconstituted

with 5ml of LRW and mixed intermittently for 5 minutes using a vortex mixture and this concentrate was used to prepare 2λ , λ , $\lambda/2$ & $\lambda/4$, where λ is the labeled claim sensitivity of Lysate.

2. Preparation of sample solution: Test samples were diluted to the required concentrations based on the formulae MVD. MVD is the maximum valid dilution, which is allowable dilution of the specimen at which the endotoxin limit can be determined. The general equation to determine MVD is $MVD = (\text{Endotoxin limit} \times \text{Concentration of sample solution}) / (\lambda)$. Where E.L is the endotoxin limit of the test sample, which is specified in the individual monograph/ based on the E.L formula if not mentioned in the monograph, in terms of volume or units of active drug (in EU/mg).

3. Lactobionic acid sample preparation: Batch No: LBA-0109, Potency=100mg/mL, E.L=0.005 Eu/mg, Lysate sensitivity is 0.0312 Eu/mL and MVD = 16. The following test dilutions are prepared by 1:16 (6.25 mg/mL), 1:8 (12.5 mg/mL), 1:4 (25 mg/mL) & 1:2 (50 mg/mL). Lactobionic acid is weak acid and having pH in the range 1 to 2.

Method

Equal volume of test sample and LAL reagent is added in a depyrogenated test tube of 10 X 75 mm and incubate this mixture at $37 \pm 1^\circ\text{C}$ for 60 ± 2 min. Then invert the tube by 180° and look for gel formation. If a gel inside the test tube is able to maintain its integrity after inverting the tube to 180° then it is a positive reaction which indicates presence of Endotoxin in the sample greater than the limit. Other than this any condition is considered as negative which indicates absence of Endotoxin in the sample (less than the lysate sensitivity).

Product Testing

For testing products equal volume of drug (sample) and LAL reagent is taken and following tubes are prepared⁵.

Negative Product Control (NPC) - Sample + LAL

Positive Product Control (PPC) - Sample + CSE (2λ) + LAL

Negative Water Control (NWC) - LRW + LAL

Positive Water Control (PWC) - LRW + CSE (2λ) + LAL

Majority of times it has been a common observation that if a product is tested directly it inhibits the LAL test and thus shows interference^{6&7}.

Interference

Interference is defined as a significant difference between the end points of positive water control and positive product control using standard endotoxin.

This interference could be either inhibition wherein the recovery of endotoxin is below than the expected or enhancement wherein the recovery of endotoxin is higher than expected

Product Validation

Product needs to be validated before start for routine testing. Validation is a test condition where an Endotoxin standard is detected with the same efficiency in a test sample as it is in LRW. This validation study consists of two different phases wherein in Phase I (Preliminary screening) involve interference testing and Phase II consists of validation of product.

Significance of product validation is that it gives information on whether there are any interfering factors in the drug product to the LAL test and also it gives an idea of the approximate levels of endotoxin content in the drug product. It also covers manufacturing of product and formulation of the product.

It is always advisable to carry out revalidation if product formulation is changed and which is likely to affect the interference pattern of the product for LAL test. Also revalidation is to be conducted for any product if there is any change in manufacturing procedures or in vendor.

RESULTS AND DISCUSSIONS

Phase I: Preliminary Screening / interference Study⁸.

In this two identical series of product dilutions (two-fold dilutions), one spiked with 2λ, and one left unspiked. The result of Phase I will tell you the non-interfering dilution (NID) of the product, which is used for the actual validation in Phase II. The non-interfering dilution (NID) is the first set of PPC that shows a gel.

Table 1: Assay results of Lactobionic acid before pH adjustment

Sample Dilution	1:2	1:4	1:8	1:16
Unspiked	--	--	--	--
Spiked	--	--	--	--

(-- no spike recovery)

This assay shows that there is inhibition up to 1:16 (MVD) in Lactobionic acid. Due to Inhibition LAL is unable to detect the endotoxins even in spiked sample After analyzing the sample using different procedures, finally In order to sort out this inhibition problem the acidic pH of the Lactobionic acid (1-2) is adjusted to 7-8 with 1N NaoH.

Table 2: Assay results of Lactobionic acid after adjusting the Acidic pH to the range of 7-8 with 1 N NaOH

Sample Dilution	1:2	1:4	1:8	1:16
Unspiked	++	--	--	--
Spiked	++	++	++	++

This assay shows no inhibition upto 1:2 dilution in Lactobionic acid and the spike recovery at 1:2 dilutions onwards. Therefore the NID is 1:2 (Lactobionic acid). It is advisable to validate the product not less than MVD/4 to take care of any batch to batch variation. So MVD/4 dilution is chosen for product validation.

Phase II: Validation of Product

For validation, test and compare two identical series of endotoxin dilutions bracketingλ; One prepared in LRW and another prepared in product diluted to the proposed test dilution. Here dilution selected for validation is 1:4. (Hot spike method).

Example of results

Table 3: Endotoxin/ Product; Negative product control: -- Geometric Mean = 0.0312 EU/mL.

Replicates	0.0625 Eu/mL	0.0312 Eu/mL	0.0156 Eu/mL	0.0078 Eu/mL
1	+	+	-	-
2	+	+	-	-
3	+	+	-	-
4	+	+	-	-

Table 4: Endotoxin/ LRW; Negative product control: -- Geometric Mean = 0.0312 EU/mL.

Replicates	0.0625 Eu/mL	0.0312 Eu/mL	0.0156 Eu/mL	0.0078 Eu/mL
1	+	+	-	-
2	+	+	-	-
3	+	+	-	-
4	+	+	-	-

Successful validation requires that both series confirm label claim (Geometric mean) within +/- one two-fold dilution.

Analytical results of the Lactobionic acid from table 2 after pH adjustment reveals NID is 1:2 (MVD/8) and the dilution selected for validation is 1:4 (MVD/4). In table 3 results show 100% recovery of the spiked Endotoxins into the product. It reveals there is no inhibition or enhancement after adjusting the pH with 1N NaOH, so there is no possibility of false positive results and we may apply the same methodology for similar kind of products.

BET applications

Large Volume Parenterals (LVPs), Multiple - ingredient drugs, Small Volume Parenterals (SVPs), Radiopharmaceuticals, Biologicals, Water system validation, Validation of Dry heat Sterilizer and Medical devices⁹.

REFERENCES

1. FDA LAL Test Guideline, USP 32, (85) Bacterial Endotoxin test (2009).
2. Bang FB. A bacterial disease of limulus Polyphemus. Bull Johns Hopkins Hosp 1956; 58:325-351.
3. USP 24-NF, 2nd Supplement, 85 Bacterial Endotoxins Test, (The USP Convention, Rockville, MD, 1999), pp 2875-9.
4. C.M.Good and H.E. Lane, Jr., the biochemistry of pyrogens, Bull.Parenter. Drug Assoc., 31, 116-120 (1977)
5. J. van Noordwijk and Y.DeJong, Comparison of the LAL test with the rabbit test: False positives and false negatives, Dev. Boil. Stand. 34, 39 - 43(1977).
6. McClosky WT; Prince CW; Van Winkle WJ; Welch H; Calvery HO.Results of first USP Collaborative study of pyrogens. J Am pharm. Assoc 1943; 32:69-73.
7. J.D. Sullivan and S.W. Watson, Purification and properties of the clotting enzyme from Limulus lysate, Biochem. Biophys. Res. Commun., 66, 848-855 (1975).
8. J.F. Cooper, Resolving LAL test interferences, J.Parenteral Sci.Tech., 44, 13-15 (1990).
9. F.C.Pearson, Limulus amebocyte lysate testing: comparative methods and reagents, Sterile Pharmaceutical Manufacturing: Applications for the1990s, Vo1.2, (M.J.Groves, W.P. Olson and M.H. Anisfe1d, Eds.), InterpharmPress, 1991, pp.185-197.